Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.

ABSTRACT:

Background

The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are hypoglycaemic agents licensed for the treatment of type 2 diabetes mellitus (T2DM). Although these drugs possess comparable efficacy and low risk of hypoglycaemia, differences in terms of route of administration (subcutaneous versus oral), effect on body weight and gastrointestinal tolerabily can impact their actual use in clinical practice. This study aimed to describe the real-world utilization of incretin-based medicines in the Italian clinical practice.

Methods

A multi-database, population-based, descriptive, cohort study was performed using administrative data collected between 2008 and 2014 from three Italian geographic areas. Subjects aged ≥18 were selected

SUBMITTER: Roberto G 

PROVIDER: S-EPMC6367760 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature